Abstract

Context • Taiwanofungus camphoratus is a parasitic mushroom found in the heartwood of Cinnamomum kanehirai and is used as a nutritional supplement. It has an anticancer action, both alone and synergistically with amphotericin B (AmB). Objective • The study intended to assess the efficacy of a T camphoratus ethanol extract (TCEE) combined with AmB for patients with metastatic cancer whose cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy. Design • The research team performed a retrospective analysis as a pilot study. Setting • The study took place at a single hospital (Taipei Medical University Hospital, Taipei, Taiwan). Participants • Participants were 9 patients at the hospital who were terminally ill with metastatic cancer. Interventions • The participants had received daily doses of 2-3 g of the TCEE in combination with a weekly dose of 20-25 mg of AmB in 500 cc of 5% glucose water, given intravenously in 4-6 h. Outcome Measures • Outcome measures included (1) a primary evaluation index measuring the efficacy of the treatment; (2) a measure of tumor burden that was estimated using the response evaluation criteria in solid tumors (RECIST 1.1), (3) a secondary evaluation index measuring survival duration, and (4) safety. Results • The mean treatment time was 54.4 ± 18.3 wk. At the end of the study, 2 patients showed a continued complete response, 1 patient had a continued partial response, and 1 patient showed a stable disease. The other 5 participants had times to progression ranging from 24 to 48 wk, with a mean of 35.6 wk. The mean survival time was 57.8 ± 18.5 wk, and 5 patients were still alive at the end of the study. Conclusions • For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression. The preliminary results reported here can be used to guide a future, more extensive clinical study of the combination.

Original languageEnglish
JournalAlternative Therapies in Health and Medicine
Volume24
Issue number12
Publication statusPublished - Dec 1 2018

Fingerprint

Amphotericin B
Drug Therapy
Neoplasms
Ethanol
Cinnamomum
Outcome Assessment (Health Care)
Terminally Ill
Agaricales
Tumor Burden
Taiwan
Disease Progression
Research Design
Survival Rate
Safety
Glucose
Survival
Water
Therapeutics

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

@article{3734f843a67e4bbaba947308d5433c86,
title = "Taiwanofungus camphoratus combined with amphotericin b for metastatic cancer patients unresponsive to or unwilling to undergo chemotherapy: A pilot study",
abstract = "Context • Taiwanofungus camphoratus is a parasitic mushroom found in the heartwood of Cinnamomum kanehirai and is used as a nutritional supplement. It has an anticancer action, both alone and synergistically with amphotericin B (AmB). Objective • The study intended to assess the efficacy of a T camphoratus ethanol extract (TCEE) combined with AmB for patients with metastatic cancer whose cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy. Design • The research team performed a retrospective analysis as a pilot study. Setting • The study took place at a single hospital (Taipei Medical University Hospital, Taipei, Taiwan). Participants • Participants were 9 patients at the hospital who were terminally ill with metastatic cancer. Interventions • The participants had received daily doses of 2-3 g of the TCEE in combination with a weekly dose of 20-25 mg of AmB in 500 cc of 5{\%} glucose water, given intravenously in 4-6 h. Outcome Measures • Outcome measures included (1) a primary evaluation index measuring the efficacy of the treatment; (2) a measure of tumor burden that was estimated using the response evaluation criteria in solid tumors (RECIST 1.1), (3) a secondary evaluation index measuring survival duration, and (4) safety. Results • The mean treatment time was 54.4 ± 18.3 wk. At the end of the study, 2 patients showed a continued complete response, 1 patient had a continued partial response, and 1 patient showed a stable disease. The other 5 participants had times to progression ranging from 24 to 48 wk, with a mean of 35.6 wk. The mean survival time was 57.8 ± 18.5 wk, and 5 patients were still alive at the end of the study. Conclusions • For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression. The preliminary results reported here can be used to guide a future, more extensive clinical study of the combination.",
author = "Tai, {Cheng Jeng} and Shi, {Yeu Ching} and Tai, {Chen Jei} and Kuo, {Li Jen} and Chen, {Ray Jade} and Chang, {Yu Jia} and Ching Tzao and Wu, {Chih Hsiung} and Chang, {Chun Chao} and Chiou, {Hung Yi} and Su, {Ching Hua}",
year = "2018",
month = "12",
day = "1",
language = "English",
volume = "24",
journal = "Alternative Therapies in Health and Medicine",
issn = "1078-6791",
publisher = "InnoVision Communications",
number = "12",

}

TY - JOUR

T1 - Taiwanofungus camphoratus combined with amphotericin b for metastatic cancer patients unresponsive to or unwilling to undergo chemotherapy

T2 - A pilot study

AU - Tai, Cheng Jeng

AU - Shi, Yeu Ching

AU - Tai, Chen Jei

AU - Kuo, Li Jen

AU - Chen, Ray Jade

AU - Chang, Yu Jia

AU - Tzao, Ching

AU - Wu, Chih Hsiung

AU - Chang, Chun Chao

AU - Chiou, Hung Yi

AU - Su, Ching Hua

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Context • Taiwanofungus camphoratus is a parasitic mushroom found in the heartwood of Cinnamomum kanehirai and is used as a nutritional supplement. It has an anticancer action, both alone and synergistically with amphotericin B (AmB). Objective • The study intended to assess the efficacy of a T camphoratus ethanol extract (TCEE) combined with AmB for patients with metastatic cancer whose cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy. Design • The research team performed a retrospective analysis as a pilot study. Setting • The study took place at a single hospital (Taipei Medical University Hospital, Taipei, Taiwan). Participants • Participants were 9 patients at the hospital who were terminally ill with metastatic cancer. Interventions • The participants had received daily doses of 2-3 g of the TCEE in combination with a weekly dose of 20-25 mg of AmB in 500 cc of 5% glucose water, given intravenously in 4-6 h. Outcome Measures • Outcome measures included (1) a primary evaluation index measuring the efficacy of the treatment; (2) a measure of tumor burden that was estimated using the response evaluation criteria in solid tumors (RECIST 1.1), (3) a secondary evaluation index measuring survival duration, and (4) safety. Results • The mean treatment time was 54.4 ± 18.3 wk. At the end of the study, 2 patients showed a continued complete response, 1 patient had a continued partial response, and 1 patient showed a stable disease. The other 5 participants had times to progression ranging from 24 to 48 wk, with a mean of 35.6 wk. The mean survival time was 57.8 ± 18.5 wk, and 5 patients were still alive at the end of the study. Conclusions • For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression. The preliminary results reported here can be used to guide a future, more extensive clinical study of the combination.

AB - Context • Taiwanofungus camphoratus is a parasitic mushroom found in the heartwood of Cinnamomum kanehirai and is used as a nutritional supplement. It has an anticancer action, both alone and synergistically with amphotericin B (AmB). Objective • The study intended to assess the efficacy of a T camphoratus ethanol extract (TCEE) combined with AmB for patients with metastatic cancer whose cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy. Design • The research team performed a retrospective analysis as a pilot study. Setting • The study took place at a single hospital (Taipei Medical University Hospital, Taipei, Taiwan). Participants • Participants were 9 patients at the hospital who were terminally ill with metastatic cancer. Interventions • The participants had received daily doses of 2-3 g of the TCEE in combination with a weekly dose of 20-25 mg of AmB in 500 cc of 5% glucose water, given intravenously in 4-6 h. Outcome Measures • Outcome measures included (1) a primary evaluation index measuring the efficacy of the treatment; (2) a measure of tumor burden that was estimated using the response evaluation criteria in solid tumors (RECIST 1.1), (3) a secondary evaluation index measuring survival duration, and (4) safety. Results • The mean treatment time was 54.4 ± 18.3 wk. At the end of the study, 2 patients showed a continued complete response, 1 patient had a continued partial response, and 1 patient showed a stable disease. The other 5 participants had times to progression ranging from 24 to 48 wk, with a mean of 35.6 wk. The mean survival time was 57.8 ± 18.5 wk, and 5 patients were still alive at the end of the study. Conclusions • For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression. The preliminary results reported here can be used to guide a future, more extensive clinical study of the combination.

UR - http://www.scopus.com/inward/record.url?scp=85063067139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063067139&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85063067139

VL - 24

JO - Alternative Therapies in Health and Medicine

JF - Alternative Therapies in Health and Medicine

SN - 1078-6791

IS - 12

ER -